Skip to main content

Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2


Prostaglandins can inhibit the generation of lymphokine-activated killer (LAK) cells by interleukin-2 (IL-2) whereas indomethacin augmented the induction of LAK cells by inhibiting prostaglandin synthesis. In the present study we demonstrate that prostaglandin E2 substantially inhibited the generation of both LAK and antibody-dependent cellular cytotoxicity (ADCC) activity by IL-2. In addition, indomethacin enhanced the induction of LAK activity and ADCC in splenocytes exposed to IL-2 in vitro. The effect of indomethacin was dose-dependent, reaching an optimal effect at 1 µM when 100–1000 units/ml IL-2 were employed. The effect of indomethacin on the generation of ADCC was seen in cells taken from both tumor-bearing mice and normal mice. ADCC induced by IL-2 was augmented by culturing cells from the spleen, liver and lungs, in the presence of indomethacin. ADCC induced in the presence of IL-2 and indomethacin was mediated by cells that were mainly plastic non-adherent cells and expressed the asialo-GM1 glycolipid. The potential of indomethacin in combined therapy with cytokines and specific anti-tumor monoclonal antibodies is discussed.

This is a preview of subscription content, access via your institution.


  1. 1.

    Brunda MJ, Herberman RB, Holden HT (1980) Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124: 2682

    Google Scholar 

  2. 2.

    Eisenthal A, Rosenberg SA (1989) Systemic induction of cells mediating antibody dependent cellular cytotoxicity (ADCC) following the administration of interleukin-2 Cancer Res 49: 6953

    Google Scholar 

  3. 3.

    Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA (1987) Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 2771

    Google Scholar 

  4. 4.

    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA (1988) Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 48: 7140

    Google Scholar 

  5. 5.

    Eisenthal A, Shiloni E, Rosenberg SA (1988) Characterization of IL-2-induced murine cells which exhibit ADCC activity. Cell Immunol 115: 257

    Google Scholar 

  6. 6.

    Fulton AM (1988) Inhibition of experimental metastasis with indomethacin: Role of macrophages and natural killer cells. Prostaglandins 35: 413

    Google Scholar 

  7. 7.

    Goodwin JS, Bankhurst AD, Messner RP (1977) Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 146: 1719

    Google Scholar 

  8. 8.

    Henney CS, Bourne HR, Lichtenstein LM (1971) The role of 3' 5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol 108: 1526

    Google Scholar 

  9. 9.

    Honda M, Steinberg AD (1984) Effects of prostaglandin E2 on responses of T-cell subsets to mitogen and autologous non-T-cell stimulation. Clin Immunol Immunopathol 33: 111

    Google Scholar 

  10. 10.

    Ibayashi Y, Hoon DS, Golub SH (1987) The regulatory effect of adherent cells on lymphokine activated killer cells. Cell Immunol 110: 365

    Google Scholar 

  11. 11.

    Kanar MC, Thiele DL, Ostensen M, Lipsky PE (1988) Regulation of human natural killer (NK) cell function: induction of killing of an NK-resistant renal carcinoma cell line. J Clin Immunol 8: 69

    Google Scholar 

  12. 12.

    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masunio T, Kishimoto S (1988) Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 48: 1173

    Google Scholar 

  13. 13.

    Lala PK, Parhar RS (1988) Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin-2: characteristics of killer cells generated in situ. Cancer Res 48: 1072

    Google Scholar 

  14. 14.

    Lala PK, Kennedy TG, Parhar RS (1988) Suppression of lymphocyte alloreactivity by early gestational human decidua II. Characterization of the suppressor mechanisms. Cell Immunol 116: 411

    Google Scholar 

  15. 15.

    Leung KH, Mihich E (1980) Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288: 597

    Google Scholar 

  16. 16.

    Murray JL, Down J, Hersh EM (1986) In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. J Biol Response Mod 5: 12

    Google Scholar 

  17. 17.

    Ogawa M, Mori T, Mori Y, Ueda S, Yoshida H, Kato I, Iesato K, Wakashin Y, Wakashin M, Okuda K (1988) Inhibitory effects of prostaglandin E1 on T-cell mediated cytotoxicity against isolated mouse liver cells. Gastroenterology 94: 1024

    Google Scholar 

  18. 18.

    Okumura Y, Ishibashi H, Shirahama M, Kurokawa S, Kudo J, Okubo H, Niho Y (1987) Kupffer cells modulate natural killer cell activity in vitro by producing prostaglandins. Cell Immunol 107: 89

    Google Scholar 

  19. 19.

    Parhar RS, Lala PK (1987) Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin-2. J Exp Med 165: 14

    Google Scholar 

  20. 20.

    Pedersen BK, Oxholm P, Klarlund K (1986) Characterization of the in vivo and in vitro effects of indomethacin on human natural killer cell activity. Allergy 41: 532

    Google Scholar 

  21. 21.

    Pedersen BK, Kharazmi A, Svenson M (1988) Down-regulation of natural killer cell activity by autologous polymorphonuclear leucocytes. Role of indomethacin. Allergy 43: 17

    Google Scholar 

  22. 22.

    Pelus LM, Ottmann OG, Nocka KH (1988) Synergistic inhibition of human bone marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-α, and γ, and an effect mediated by tumor necrosis factor. J Immunol 140: 479

    Google Scholar 

  23. 23.

    Remick DG, Larrick JW, Nguyen DT, Kunkel SL (1987) Stimulation of prostaglandin E2 and thromboxane B2 production by human monocytes in response to interleukin-2. Biochem Biophys Res Commun 147: 86

    Google Scholar 

  24. 24.

    Remick DG, Kunkel SL, Higashi GI, Hiserodt JC (1988) Suppression of natural killer cytolytic activity in mice undergoing pulmonary granulomatous inflammation. J Immunol 140: 2225

    Google Scholar 

  25. 25.

    Rita M, Young I, Young ME, Kim K (1988) Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res 48: 6826

    Google Scholar 

  26. 26.

    Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin 2 produced inEscherichia coli. Science 223: 1412

    Google Scholar 

  27. 27.

    Sachs DH, Cone JL (1973) A murine B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. J Exp Med 138: 1289

    Google Scholar 

  28. 28.

    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA (1987) Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138: 1992

    Google Scholar 

  29. 29.

    Shultz RM, Pavlidis NA, Slylos WA, Chirigos MA (1978) Regulation of macrophage tumoricidal functions: a role of prostaglandins of E-series. Science 202: 320

    Google Scholar 

  30. 30.

    Sileghem M, Darji A, Remels L, Hamers R, Baetselier PD (1989) Different mechanism account for the suppression of interleukin 2 production and the suppression of interleukin 2 receptor expression in trypanosoma brucei-infected mice. Eur J Immunol 19: 119

    Google Scholar 

  31. 31.

    Smith KA, Lachman LB, Oppenheim JJ, Favata FM (1980) The functional relationship of the interleukins. J Exp Med 151: 1551

    Google Scholar 

  32. 32.

    Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R (1987) Systemic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47: 5725

    Google Scholar 

  33. 33.

    Voth R, Chemielarczyk W, Storch E, Kirchner H (1986) Induction of natural killer cell activity in mice by injection of indomethacin. Nat Immun Cell Growth Regul 5: 314

    Google Scholar 

  34. 34.

    Webb DR, Nowowiejski I (1975) The role of prostaglandins in the control of primary 19S immune response to SRBC. Cell Immunol 33: 1

    Google Scholar 

  35. 35.

    Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716

    Google Scholar 

  36. 36.

    Young MR, Newby M (1986) Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice. J Natl Cancer Inst 77: 1255

    Google Scholar 

  37. 37.

    Young MR, Endicott RA, Duffie GP, Wepsic HT (1987) Suppressor alveolar macrophages in mice bearing metastatic Lewis lung carcinoma tumors. J Leukocyte Biol 42: 682

    Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eisenthal, A. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2. Cancer Immunol Immunother 31, 342–348 (1990).

Download citation


  • Monoclonal Antibody
  • Cancer Research
  • Prostaglandin
  • Indomethacin
  • Normal Mouse